Pharmacology of estradiol valerate/dienogest.

@article{Teichmann2003PharmacologyOE,
  title={Pharmacology of estradiol valerate/dienogest.},
  author={Alexander Tobias Teichmann},
  journal={Climacteric : the journal of the International Menopause Society},
  year={2003},
  volume={6 Suppl 2},
  pages={17-23}
}
The particular features of the pharmacology of a new continuous regimen for hormone replacement therapy containing 2 mg estradiol valerate (E2V) and 2 mg dienogest (DNG) (Climodien, Schering AG, Berlin, Germany) depend largely on its progestogenic component. Dienogest has the essential properties of an effective progestogen, so that it protects against endometrial proliferation and remarkably does not counteract the effects of estrogens. It is a derivative of 19-nortestosterone, but, instead of… CONTINUE READING

Similar Papers

Loading similar papers…